NCT05308212已完成2 期
Multicenter, Double-blind, Comparative, Randomized Tolerability, Safety and Immunogenicity Trial of the FLU-M® Tetra Inactivated Vaccine in Volunteers Aged 60 Years and Above
St. Petersburg Research Institute of Vaccines and Sera11 个研究点 分布在 1 个国家目标入组 633 人开始时间: 2021年3月4日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 入组人数
- 633
- 试验地点
- 11
- 主要终点
- Geometric mean titer (GMT) ratio of antibodies after vaccination
研究概览
简要总结
Comparative assessment of the tolerability, safety, and immunogenicity of the FLU-M® Tetra quadrivalent inactivated split influenza vaccine and the Ultrix® vaccine in volunteers aged 60 years and above.
详细描述
Evaluation of the tolerability, safety and immunogenicity of the inactivated split influenza vaccine FLU-M® Tetra compared to Ultrix® vaccine in volunteers aged 60 years and above.
Volunteers were screened and randomized in three groups: the Flu-M Tetra w/p (with preservative) group, the Flu-M Tetra w/o/p (without preservative) group and the Ultrix® group. All subjects were followed up for 28 days post randomization and vaccination.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Prevention
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 60 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 是
入选标准
- •Volunteers (men and women) at the age of 60 years and above
- •Written informed consent of volunteers to participate in the clinical trial;
- •Volunteers able to fulfill requirements of the Protocol (i.e. fill out the patient's diary, come to follow-up visits);
- •For fertile women - a negative result of the pregnancy test and consent to observe adequate methods of contraception during the trial and at least two months after vaccination;
- •For fertile men - consent to observe adequate methods of contraception during the trial and at least two months after vaccination, except for men after vasectomy with documented azoospermia, and their sexual partners should use methods of contraception that ensure more than 90% reliability or be incapable of conception after a surgical sterilization or have a natural menopause for at least 2 years.
排除标准
- •History of influenza/ARVI or previous influenza vaccination during 6 months before the trial;
- •Positive result of the SARS-CoV-2 test;
- •A serious post-vaccination reaction (temperature above 40 °C, hyperemia or edema more than 8 cm in diameter) or complications (collapse or shock-like condition that developed within 48 hours after vaccination; convulsions accompanied or not accompanied by a fever due to any previous vaccination);
- •Allergic reactions to vaccine components or any previous vaccination;
- •History of allergic reaction to chicken protein;
- •History of Guillain-Barré syndrome (acute polyneuropathy);
- •Previous vaccination with rabies vaccines less than 2 months before immunization or scheduled vaccination with rabies vaccines within 1 month after immunization with the trial vaccines;
- •History of leukemia, cancer, autoimmune diseases;
- •Positive blood test results for HIV, syphilis, hepatitis B/C.
- •Volunteers who received immunoglobulin or blood products or had a blood transfusion during the last three months before the trial;
- •History of long-term use (more than 14 days) of immunosuppressants or immunomodulatory drugs for six months before the trial;
- •History of any confirmed or suspected immunosuppressive or immunodeficiency condition;
- •History of chronic diseases of the cardiovascular, bronchopulmonary, neuroendocrine systems, the gastrointestinal tract, liver, kidneys, hematopoietic, immune and endocrine system, mental disease in the acute stage or in the decompensation stage (recovery less than 4 weeks before vaccination);
- •History of eczema;
- •Treatment with glucocorticosteroids, including in small doses, as well as local use of drugs containing steroids (> 10 mg of prednisolone or its equivalent for more than 14 days before the screening);
- •Tuberculosis, neurological or mental disorders, a convulsive syndrome, including in the past medical history;
- •History of acute infectious diseases (recovery less than 4 weeks before vaccination);
- •Consumption of more than 10 units of alcohol per week or history of alcohol addiction, drug addiction or abuse of pharmaceutical products;
- •Smoking of more than 10 cigarettes per day;
- •Participation in another clinical trial during the last 3 months;
- •Pregnancy or lactation;
- •Coagulopathy, haemophilia;
- •Taking aspirin or other antiplatelet agents in high doses.
结局指标
主要结局
Geometric mean titer (GMT) ratio of antibodies after vaccination
时间窗: days 0, 28
Geometric mean titer (GMT) of antibodies in the blood serums of vaccinated people in haemagglutination inhibition assay.
次要结局
- Seroconversion factor(days 0, 28)
- Results of E immunoglobulin tests(days 0,3,28)
- Results of assessment of body temperature(days 0,1,3,7,28)
- Number of participants with abnormal neurological examinations(days 0,1,3,7,28)
- Change from baseline seroconversion rate at 28 days(days 0, 28)
- Seroprotection rate(days 0, 28)
- Frequency of development of AEs associated with the vaccination(days 0-28)
- Frequency of development of SAEs associated with the vaccination(days 0-28)
- Results of assessment of blood pressure (BP)(days 0,1,3,7,28)
- Number of participants with abnormal physical examination findings(days 0,1,3,7,28)
- Results of assessment of heart rate (HR)(days 0,1,3,7,28)
- Number of participants with abnormal ECG findings(days 0,3)
- Number of participants with abnormal complete blood counts results(days 0,3)
- Results of assessment of respiratory rate (RR)(days 0,1,3,7,28)
- Number of participants with abnormal biochemical blood tests results(days 0,3)
- Number of participants with abnormal urinalysis results(days 0,3)
研究者
研究点 (11)
Loading locations...
相似试验
已完成
3 期
Tolerability, Safety and Immunogenicity Trial of the Flu-M® Inactivated Vaccine in Volunteers Aged 18 to 60 YearsFlu, HumanInfluenzaNCT05312294St. Petersburg Research Institute of Vaccines and Sera654
已完成
3 期
The Objectives of This Study Are Comparative Assessment of the Tolerability, Safety and Immunogenicity of the Flu-M Vaccine vs. the Ultrix® Vaccine by Single Vaccination of Children Aged 6 to 17 Years.InfluenzaNCT05317767St. Petersburg Research Institute of Vaccines and Sera600
已完成
3 期
Trial of Tolerability, Safety and Immunogenicity of the Flu-M Vaccine in Children Between 6 Months and 9 Years OldInfluenza, HumanVaccinesInfection VaccinationNCT05470582St. Petersburg Research Institute of Vaccines and Sera1,066
已完成
2 期
Tolerability, Safety and Immunogenicity Trial of the Flu-M Quadro, Tetravalent Inactivated Split Influenza VaccineInfluenza, HumanInfluenza Viral InfectionsVaccine ReactionInfluenzaInfection VaccinationNCT05869201St. Petersburg Research Institute of Vaccines and Sera450
已完成
3 期
Trial of Tolerability, Reactogenicity, Safety and Immunogenicity of Flu-M [Inactivated Split Influenza Vaccine] in Pregnant WomenInfluenza, HumanVaccinesInfection VaccinationNCT05457894St. Petersburg Research Institute of Vaccines and Sera207